Janowitz, Tobias

A framework for advancing our understanding of cancer-associated fibroblasts

Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., Greten, F. R., Hingorani, S. R., Hunter, T., et al. (2020) · Nature Reviews Cancer

Cancer Cells and MetastasisTGF-β signaling in diseases

Cited by 3,863

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences

Cancer Immunotherapy and BiomarkersPancreatic and Hepatic Oncology Research

Cited by 2,100

Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity

Flint, T. R., Janowitz, T., Connell, C. M., Roberts, E. W., Denton, A. E., Coll, A. P., Jodrell, D. I., & Fearon, D. T. (2016) · Cell Metabolism

Immune cells in cancerDietary Effects on Health

Cited by 367

Exploring new routes for neuroprotective drug development in traumatic brain injury

Janowitz, T., & Menon, D. K. (2010) · Science Translational Medicine

Traumatic Brain Injury and Neurovascular DisturbancesTraumatic Brain Injury Research

Cited by 74

Reconsidering Dexamethasone for Antiemesis when Combining Chemotherapy and Immunotherapy

Janowitz, T., Kleeman, S., & Vonderheide, R. H. (2021) · The Oncologist

Cancer Immunotherapy and BiomarkersNausea and vomiting management

Cited by 42

Cystatin C is glucocorticoid responsive, directs recruitment of Trem2+ macrophages, and predicts failure of cancer immunotherapy

Kleeman, S. O., Thakir, T. M., Demestichas, B., Mourikis, N., Loiero, D., Ferrer, M., Bankier, S., Riazat-Kesh, Y. J. R. A., Lee, H., Chantzichristos, D., et al. (2023) · Cell Genomics

Immune cells in cancerCancer Immunotherapy and Biomarkers

Cited by 37

Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes

Connell, C. M., Raby, S., Beh, I., Flint, T. R., Williams, E. H., Fearon, D. T., Jodrell, D. I., & Janowitz, T. (2017) · Annals of Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 32

Cystatin C is associated with adverse COVID-19 outcomes in diverse populations

Kleeman, S. O., Cordioli, M., Timmers, P. R. H. J., Khan, A., Tober-Lau, P., Kurth, F., Demichev, V., Meyer, H. V., Wilson, J. F., Ralser, M., et al. (2022) · iScience

COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research

Cited by 3